7 citations
,
September 2023 in “JAMA Dermatology” This study reviewed treatment patterns for adults with alopecia areata in the US from 2015 to 2020, revealing that corticosteroids were the most common treatment, yet over two-thirds of patients were not receiving any treatment a year after diagnosis.
7 citations
,
October 2022 in “Advances in Therapy” This review of real-world treatment options for AA indicates that current therapies are insufficient, with high dissatisfaction rates, highlighting a need for improved solutions.
March 2026 in “Dermatology and Therapy” In this study, researchers found that patients with severe alopecia areata often experience reduced health-related quality of life, with significant levels of anxiety and depression, and these mental health impacts may correlate with the severity of their condition.
July 2024 in “The Journal of Dermatology” This study among patients with severe alopecia areata in South Korea found that 93.4% received pharmacological treatment, with 71.0% achieving hair regrowth and 59.2% experiencing major regrowth, but highlighted a critical unmet need for more effective treatment strategies.
June 2023 in “Dermatology and therapy” This study found that most dermatologists in the Middle East manage mild to severe alopecia areata primarily with potent topical corticosteroids and identified long-term disease control and improved efficacy as key unmet needs.